Rolf Muller, PhD


Rolf Muller is a biotechnology leader combining science and business knowledge to build and grow successful technology companies that further healthcare and the field of personalized medicine. He has structured and guided highly efficient multi-disciplinary research and commercial teams through funding, to product development, and successful product launch into global markets.

Prior to joining BioFluidica he was the Founder and President of Biomatrica, which he developed from an idea to be a global leader in biopreservation technologies for diagnostic and health care companies. Over the last 16 years he has been involved in analyzing markets and developing strategies to position biotechnologies to maximize value. He has interacted with most of the major pharma and biotechnology companies to obtain funded development contracts, joint projects, and partnerships. In addition to raising successfully capital from investors he also raised non-dilutive capital from CDC, NCI, NIH, DARPA, In-Q-Tel and DOD. He obtained his Ph.D. in biochemistry from the Pasteur Institute in Paris France.

Judy Muller-Cohn, PhD


Judy Muller-Cohn, Ph.D. is a biotechnology leader moving scientific ideas to commercial products. She manages operations at BioFluidica overseeing commercial development of the company’s ground breaking technology to serve the growing need of the cancer diagnostic market. Previously, she founded, and for ten years was CEO, of a successful biotechnology company from idea to financing, product development, patenting, grant management, human resources, and business development.

She also serves on the boards of for-profit and non-profit organizations. Judy earned a Ph.D. in microbial biochemistry from Universite Paris VI and conducted her research at the Pasteur Institute in Paris, France.

Greg Studdard


Greg Studdard brings an expansive network of connections as well as commercial build and new technology launch experience to BioFluidica. He has successfully led several companies and sales teams with breakthrough technologies and services into new Standards of Care in Medicine during his decades long career. He was part of the then largest acquisition in diagnostics in the world when Verinata Health was acquired by Illumina in 2013.

Greg received double majors in Marketing and Management with a minor in Psychology at the University of Virginia and later received his MBA from Chadwick University, a UAB program. He launched national testing at the first prenatal screening lab in the country early in his career with NTD Labs (a Perkin-Elmer/Revvity and later Eurofins company). Later he brought new technology advances in screening and genetic testing to market at GeneCare (Alere at acquisition and now Optum). He brings management, sales, partnering, marketing and managed care experience from his varied experiences, which includes running an Ultrasound company as well as being CCO at a Diabetes company.

Yipeng Wang, MD, PhD


With over twenty years of experience in oncology, liquid biopsy and molecular diagnostics space, Dr. Wang brings his expertise in clinical research, product development and management to BioFluidica in 2022. As Vice President of Translational Medicine at BioFluidica, he is responsible for driving and managing disease initiatives and clinical applications.

Prior to joining BioFluidica, Dr. Wang served as the Vice President of Informatics at Mindera Health, Senior Director of Translational Research at Epic Sciences, Director of Bioinformatics at AltheaDx, where he led the development of multiple clinical tests, genomics analysis pipelines, and machine learning algorithms. Mr. Wang has over 60 peer-reviewed publications in journals including sciences, PNAS, Blood and Cancer Research etc. He earned a M.D. and Ph.D from JiLin University and a certificate in business management.

Gordon Vansant, BSB, PhD


Dr. Vansant received his BS in Biochemistry from East Carolina University in North Carolina and his PhD in Molecular Biology from the University of Hawaii in Oahu.  He followed his doctorate work with two post-doctorate fellowships, one at Sidney Kimmel Cancer Center and one at University of California, both in San Diego.

Dr. Vansant then started his career at The Immune Response Corporation where he worked on discovery projects for neurological disorders and neurotrauma and then at Burstein Labs on unique PCR platform development.  Both included collaboration with Dr. Kary Mullis.  Dr. Vansant then joined Althea, where he had roles of increasing responsibility as Director of Technology Development, Analytical Services, and then as Director of Business Development. Other successful business development roles were at Metabolon, Somalogic, EPIC Sciences, and Interpace, and ResearchDx.

Dr. Vansant has over 20 years of experience in nucleic acid, proteomic and biochemical analysis. His scientific and business development roles have been in GLP certified, and CLIA / CAP accredited CRO laboratories.  His work has included technology transfer and the development of innovative technologies for biomarker and drug development support, with an emphasis on oncology.